Cargando…

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma

Multiple myeloma (MM) is characterized by heterogeneity of tumor cells. The study of tumor cells from blood, bone marrow, plasmacytoma, etc., allows us to identify similarities and differences in tumor lesions of various anatomical localizations. The aim of this study was to compare the loss of hete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soloveva, Maiia, Solovev, Maksim, Nikulina, Elena, Risinskaya, Natalya, Biderman, Bella, Yakutik, Igor, Obukhova, Tatiana, Mendeleeva, Larisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957234/ https://www.ncbi.nlm.nih.gov/pubmed/36833278 http://dx.doi.org/10.3390/genes14020351

Ejemplares similares

P842: RAS-ERK PATHWAY GENES MUTATIONS IN THE LESIONS FROM VARIOUS TUMOR LOCI IN MULTIPLE MYELOMA
por: Soloveva, Maiia, et al.
Publicado: (2023)

PB2145: IMPACT OF A SIZE OF BONE PLASMACYTOMA ON THE COURSE OF MULTIPLE MYELOMA
por: Mamaeva, Elizaveta, et al.
Publicado: (2023)

PB1954: COMPARING STR PROFILES OF DNA ISOLATED FROM DIVERSE TUMOR SITES IN MULTIPLE MYELOMA
por: Firsova, M., et al.
Publicado: (2022)

Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry
por: Firsova, Maiia V., et al.
Publicado: (2020)

Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL
por: Risinskaya, Natalya, et al.
Publicado: (2022)

PB1836: LOSS OF HETEROZYGOSITY IN AML PATIENTS WITH INV(16)
por: Bessmertniy, Dmitry, et al.
Publicado: (2023)

PB1962: COMPARISON OF EXPRESSION OF NSD2, CYCLIN D1 AND C-MAF BY PLASMA CELLS IN BONE MARROW AND BONE PLASMACYTOMA IN PATIENTS WITH PLASMA CELL MYELOMA
por: Mamaeva, E., et al.
Publicado: (2022)

Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors
por: Biderman, Bella V., et al.
Publicado: (2023)

PB1977: SPECTRUM OF INFECTIOUS COMPLICATIONS FOLLOWING TRANSPLANTATION OF AUTOLOGOUS BLOOD STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Abakumova, A., et al.
Publicado: (2022)

PB2077: COMPARISON OF PLASMA CELL PERCENTAGE BY BONE MARROW ASPIRATE MORPHOLOGY AND CD138-STAINED BONE MARROW BIOPSY IN SMOLDERING MYELOMA TO PREDICT TRANSFORMATION TO SYMPTOMATIC MYELOMA
por: Cashman, Helen, et al.
Publicado: (2023)

Heterozygosity for cervid S138N polymorphism results in subclinical CWD in gene-targeted mice and progressive inhibition of prion conversion
por: Arifin, Maria I., et al.
Publicado: (2023)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

Carbohydrate Metabolism Parameters of Adult Glial Neoplasms According to Immunohistochemical Profile
por: Obukhova, Larisa, et al.
Publicado: (2022)

STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
por: Risinskaya, Natalya, et al.
Publicado: (2022)

High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma
por: Ibata, Soushi, et al.
Publicado: (2018)

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma
por: Papadimitriou, Maria-Alexandra, et al.
Publicado: (2023)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

Relationship between Glutathione-Dependent Enzymes and the Immunohistochemical Profile of Glial Neoplasms
por: Obukhova, Larisa, et al.
Publicado: (2022)

Glutathione and Its Metabolic Enzymes in Gliomal Tumor Tissue and the Peritumoral Zone at Different Degrees of Anaplasia
por: Obukhova, Larisa, et al.
Publicado: (2022)

Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
por: Cengiz, Arzu, et al.
Publicado: (2018)

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()
por: Krishnan, Sabna Rajeev, et al.
Publicado: (2016)

Accumulation of STR-Loci Aberrations in Subclones of Jurkat Cell Line as a Model of Tumor Clonal Evolution
por: Risinskaya, Natalya, et al.
Publicado: (2023)

PB2031: CD269, CD319 EXPRESSION ON MALIGNANT PLASMA CELLS AND SOLUBLE BCMA, SLAMF7 PROTEINS COMPARATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Startsev, A., et al.
Publicado: (2022)

Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases
por: Gorodetskiy, Vadim, et al.
Publicado: (2021)

Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma
por: Choudhuri, Jui, et al.
Publicado: (2023)

STAT3 mutations in “gray-zone” cases of T-cell large granular lymphocytic leukemia associated with autoimmune rheumatic diseases
por: Gorodetskiy, Vadim, et al.
Publicado: (2022)

Paragraph 138
por: Lippe, Ad.
Publicado: (1887)

PB1792: NGS VS PCR FOR THE DETECTION OF NPM1 GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA.
por: Severina, N., et al.
Publicado: (2022)

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
por: Kis, Olena, et al.
Publicado: (2017)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

A new method to detect loss of heterozygosity using cohort heterozygosity comparisons
por: Green, Michael R, et al.
Publicado: (2010)

PB2344: STR-LOCI ALLELE IMBALANCE AT 9P24.1 AND PD-L1 EXPRESSION IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.
por: Abdurashidova, Runiza, et al.
Publicado: (2023)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

Contents of Volume 138
Publicado: (2008)

Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients
por: Batorov, Egor V., et al.
Publicado: (2020)

Assessment of Heterozygosity and Genome-Wide Analysis of Heterozygosity Regions in Two Duroc Pig Populations
por: Ruan, Donglin, et al.
Publicado: (2022)

Deep Learning Accurately Quantifies Plasma Cell Percentages on CD138-Stained Bone Marrow Samples
por: Fu, Fred, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_debd49f8p29bps2gof5tfmgcnh